Question

A 57-year-old with T2D and ASCVD asks about lipid therapy. Which regimen is consistent with current U.S. guidelines?

Accepted Answer

High-intensity statin aiming ≥50% LDL-C reduction; consider ezetimibe or PCSK9 if LDL-C remains ≥70 mg/dL

Answer

Moderate-intensity statin regardless of ASCVD

Answer

Niacin to raise HDL as first-line

Answer

Fenofibrate to lower triglycerides instead of statin

Answer

No statin if baseline LDL-C 80 mg/dL

Practice question

A 57-year-old with T2D and ASCVD asks about lipid therapy. Which regimen is consistent with current U.S. guidelines?